Introduction:

Erythropoietin is hormone secreted by kidney which stimulates red blood cells production in the bone marrow and those are also known as hematopoietin or hemopoietin. Erythropoietin drugs are used for treatment of anemia induced from cancer, multiple myloma, and HIV associated anemia. Synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, epoetin delta, and epoetin omega are developed by recombinant DNA technology researchers. Normal levels of erythropoietin administered in a range from 4 up to 24 mU/ml (milliunits per millilitre). Erythropoiesis-stimulating agents are medications which stimulate the bone marrow to form red blood cells. They are used to treat anemia due to end stage renal disorder, chemotherapy, operation, or certain treatments in HIV/AIDS. In these situations they decrease the necessity for blood transfusions. Erythropoietin Drugs Market accounted for US$ 11 billion in 2020 and is estimated to be US$ 25.9 billion by 2030 and is anticipated to register a CAGR of 8.9%.

Increasing prevalence of anemia and other diseases

Increasing prevalence of anemia, caner, chronic kidney disease, bone marrow dysfunction, and HIV are major factor driving growth of the erythropoietin drugs market. According to data published by National Center for Biotechnology Information, Europe medicine agency approved in the United States of America (US) for treatment of chemotherapy-induced anaemia (CIA) patients with non-myeloid malignancies involved Epoetin alfa and darbepoetin alfa. In addition, rising incidences of deficiency of iron, vitamin B12, and folic acid due to desk-bound lifestyle increases the demand for erythropoietin drugs market.

Blood transfusion during surgeries

Furthermore, blood transfusion during surgeries and treatment of solid tumors, malignant lymphoma or multiple myeloma, and cardiovascular status is also expected to propel the target market. Moreover, growing drug patent expiration is shifting vendors to emphasize on using biosimilar medicines that have same therapeutic effect with lower cost is another factor which supports the growth of target market. However, cost-efficiency regarding therapeutics medication process and longer duration of treatments are some factors that restrain growth of the erythropoietin drugs market.

The erythropoietin drugs market on the basis of drug class, product, application, and region.

On the basis of drug class, the target market is categorized into biologics and biosimilar. On the basis of product, the erythropoietin drugs market is bifurcated into epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. Others product sub-segment is classified into pegylated erythropoietin and carbamylated erythropoietin. On the basis of application, the target market is segmented into cancer, hematology, renal diseases, and neurology.

Regional Insight

For detailed understanding of market dynamics, the erythropoietin drugs market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the erythropoietin drugs market. In 2018, the North America erythropoietin drugs market is expected to account for major revenue share in erythropoietin drugs market, followed by other regions. This is attributed to patent expiration of biologics and various players have entered the market in countries of the North America region. For instance, Amgen’s patent for Epogen expired in 2015. Europe erythropoietin drugs market is accounted for significant market share in the erythropoietin drugs market, in 2018. This is due to large patient pool, developed healthcare infrastructure and better reimbursement scenario. The pharmaceutical companies continue to introduce biosimilar in the region to compete against the reference drugs in European countries. Abaseamed, binocrit, and epoetin alpha hexal are biosililars approved by Europe medicine agency. Asia Pacific erythropoietin drugs market is expected to have fastest growth rate in the erythropoietin drugs market, owing to increasing incidences of chronic diseases in the countries such as India and China of the  region.

                                     

Attribute	Details
Base year for estimation	2020
Forecast period	2020 – 2029
Market representation	Revenue in USD Million & CAGR from 2020 – 2029
Market Segmentation	By Drug Class: Biologics and Biosimilar By Product: Epoetin-Alfa, Epoetin-Beta, Darbepoetin-Alfa, and Others (Pegylated Erythropoietin and Carbamylated Erythropoietin) By Application: Cancer, Hematology, Renal Diseases, and Neurology
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Detailed Segmentation:

Erythropoietin Drugs Market, By Drug Class:

• Biologics
  • Biosimilar

Erythropoietin Drugs Market, By Product:

• Epoetin-alfa
  • Others (pegylated erythropoietin and carbamylated erythropoietin)
  • Darbepoetin-alfa
  • Epoetin-beta

Erythropoietin Drugs Market, By Application:

• Cancer
  • Neurology
  • Renal diseases
  • Hematology

Erythropoietin Drugs Market, By Region:

• North America
  • Africa
    • Africa Erythropoietin Drugs Market, By Drug Class
    • Africa Erythropoietin Drugs Market, By Product
    • Africa Erythropoietin Drugs Market, By Application
    • Africa Erythropoietin Drugs Market, By Country
      • North Africa
      • Central Africa
      • South Africa
  • Middle East
    • Middle East Erythropoietin Drugs Market, By Drug Class
    • Middle East Erythropoietin Drugs Market, By Product
    • Middle East Erythropoietin Drugs Market, By Application
    • Middle East Erythropoietin Drugs Market, By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Latin America
    • Latin America Erythropoietin Drugs Market, By Drug Class
    • Latin America Erythropoietin Drugs Market, By Product
    • Latin America Erythropoietin Drugs Market, By Application
    • Latin America Erythropoietin Drugs Market, By Country
      • Brazil
      • Mexico
      • Rest of Latin America
  • Asia-Pacific
    • Asia-Pacific Erythropoietin Drugs Market, By Drug Class
    • Asia-Pacific Erythropoietin Drugs Market, By Product
    • Asia-Pacific Erythropoietin Drugs Market, By Application
    • Asia-Pacific Blockchain Market, By Country
      • China
      • India
      • Australia
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • Europe Erythropoietin Drugs Market, By Drug Class
    • Europe Erythropoietin Drugs Market, By Product
    • Europe Erythropoietin Drugs Market, By Application
    • Europe Erythropoietin Drugs Market, By Country
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • North America Erythropoietin Drugs Market, By Drug Class
  • North America Erythropoietin Drugs Market, By Product
  • North America Erythropoietin Drugs Market, By Application
  • North America Erythropoietin Drugs Market, By Country
    • U.S.
    • Canada

Some of the prominent players operating in the erythropoietin drugs market include Johnson & Johnson, Celltrion, Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Amgen, Inc, F. Hoffmann-La Roche Ltd., LG Life Sciences Ltd., Biocon Limited, Intas Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, and Dr. Reddy’s Laboratories Ltd. The market players operating in the erythropoietin drugs market are focusing on new product launches in order to get competitive edge in the target market. For instance, in May 2018, Pfizer Inc. announced United States Food and Drug Administration (USFDA) approved “RETACRIT®” (epoetin alfa-epbx) is a biosimilar to Epogen® and Procrit® (epoetin alfa).

• Johnson & Johnson
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

• Celltrion, Inc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

• Pfizer Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

• Amgen, Inc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

• LG Life Sciences Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

• Biocon Limited
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

• Intas Pharmaceuticals Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

• Sun Pharmaceutical Industries Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

• Dr. Reddy’s Laboratories Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance

1. Research Objective and Assumption
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Preview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Drug Class
     • Market Snippet, By Product
     • Market Snippet, By Application
     • Market Snippet, By Region
   • Opportunity Map Analysis
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
   • Market Trends
   • Product Launch
   • Merger and Acquisitions
   • Recent Approvals
   • Impact Analysis
   • PEST Analysis
   • Porter’s Analysis
4. Market Segmentation, By Drug Class, 2019 – 2029, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
     • Y-o-Y Growth Analysis (%), 2019 – 2029
     • Segment Trends
   • Biologics
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
   • Biosimilar
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
5. Market Segmentation, By Product, 2019 – 2029, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
     • Y-o-Y Growth Analysis (%), 2019 – 2029
     • Segment Trends
   • Epoetin-Alfa
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
   • Epoetin-Beta
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
   • Darbepoetin-Alfa
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
   • Others (Pegylated Erythropoietin and Carbamylated Erythropoietin)
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
6. Market Segmentation, By Application, 2019 – 2029, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
     • Y-o-Y Growth Analysis (%), 2019 – 2029
     • Segment Trends
   • Cancer
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
   • Hematology
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
   • Renal diseases
   • Neurology
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
7. Global Market, By Region, 2019 – 2029, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
     • Y-o-Y Growth Analysis (%), 2019 – 2029
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Bn), By Drug Class, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Application, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Bn), By Drug Class, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Application, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
       • Germany
       • UK
       • France
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Bn), By Drug Class, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Application, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
       • China
       • India
       • Australia
       • Japan
       • South Korea
       • Rest of Asia Pacific
   • Latin America
     • Market Size and Forecast (US$ Bn), By Drug Class, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Application, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
       • Brazil
       • Mexico
       • Argentina
       • Rest of Latin America
   • Middle East
     • Market Size and Forecast (US$ Bn), By Drug Class, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Application, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
       • GCC
       • Israel
       • Rest of Middle East
   • Africa
     • Market Size and Forecast (US$ Bn), By Drug Class, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Product, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Application, 2019 – 2029
     • Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
       • South Africa
       • Central Africa
       • North Africa
8. Competitive Landscape
   • Heat Map Analysis
   • Company Profiles
     • Johnson & Johnson
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Celltrion, Inc
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Pfizer Inc.
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Teva Pharmaceutical Industries Ltd
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Amgen, Inc
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • F. Hoffmann-La Roche Ltd
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • LG Life Sciences Ltd.
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Biocon Limited
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Intas Pharmaceuticals Ltd
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Sun Pharmaceutical Industries Ltd
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Dr. Reddy’s Laboratories Ltd
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
   • Analyst Views
9. Section
   • Research Methodology
   • About Us
   • Contact